Clearside Biomedical Stock: A Pivotal 2022 Ahead (NASDAQ:CLSD)
Clearside Biomedical's XIPERE was officially launched by partner Bausch + Lomb in Q1. See why I think a gene therapy partnership is likely upcoming for CLSD.
Source: seekingalpha.com